Evidence map›Paper›PMID 38516394›Full record

ReviewFrontiers in surgery2024

Advancement of fluorescent aminopeptidase probes for rapid cancer detection-current uses and neurosurgical applications.

Takenori Shimizu, Shota Tanaka, Yosuke Kitagawa, Yusuke Sakaguchi, Mako Kamiya, Shunsaku Takayanagi, Hirokazu Takami, Yasuteru Urano, Nobuhito Saito

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Takenori Shimizu *Department of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shota Tanaka *Department of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yosuke KitagawaDepartment of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yusuke SakaguchiDepartment of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mako KamiyaDepartment of Life Science and Technology, Tokyo Institute of Technology, Tokyo, Japan.
Shunsaku TakayanagiDepartment of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hirokazu TakamiDepartment of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yasuteru UranoLaboratory of Chemical Biology and Molecular Imaging, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nobuhito SaitoDepartment of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPTokyo Institute of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical resection is considered for most brain tumors to obtain tissue diagnosis and to eradicate or debulk the tumor. Glioma, the most common primary malignant brain tumor, generally has a poor prognosis despite the multidisciplinary treatments with radical resection and chemoradiotherapy. Surgical resection of glioma is often complicated by the obscure border between the tumor and the adjacent brain tissues and by the tumor's infiltration into the eloquent brain. 5-aminolevulinic acid is frequently used for tumor visualization, as it exhibits high fluorescence in high-grade glioma. Here, we provide an overview of the fluorescent probes currently used for brain tumors, as well as those under development for other cancers, including HMRG-based probes, 2MeSiR-based probes, and other aminopeptidase probes. We describe our recently developed HMRG-based probes in brain tumors, such as PR-HMRG, combined with the existing diagnosis approach. These probes are remarkably effective for cancer cell recognition. Thus, they can be potentially integrated into surgical treatment for intraoperative detection of cancers.

Indexed as

5-aminolevulinic acidglioblastomagliomaglutamylprolyl-HMRGhydroxymethyl rhodamine greenγ-glutamyl-HMRG

Identifiers

PMID38516394
PMCPMC10954885
OpenAlexW4392559257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.